Core Insights - The study results presented at the ESMO Asia Congress 2025 indicate that the combination therapy of osemitamab with nivolumab and CAPOX shows promising clinical benefits for patients with advanced gastric or gastroesophageal junction adenocarcinoma [1][2] Group 1: Clinical Efficacy - The updated efficacy analysis from the TranStar102 trial shows a median progression-free survival (mPFS) of 16.6 months and an objective response rate (ORR) of 68% among 26 patients with CLDN18.2 expression ≥40% and known PD-L1 CPS [1] - The median duration of response (mDoR) is reported to be 18 months, indicating sustained efficacy of the treatment [1] - Higher CLDN18.2 expression correlates with better PFS outcomes regardless of PD-L1 expression levels, suggesting consistent therapeutic benefits across different patient subgroups [1] Group 2: Safety and Tolerability - The safety profile of the combination therapy remains consistent with previously reported data, indicating good tolerability and safety [1][2] - The treatment is expected to provide significant clinical benefits to patients who urgently need more effective treatment options for advanced gastric or gastroesophageal junction adenocarcinoma [2]
创胜集团-B(06628.HK)于ESMO Asia公布osemitamab三联疗法一线治疗胃或胃食管结合部腺癌的I/II期(Transtar102)更新疗效数据